Lars Aagaard
Overview
Explore the profile of Lars Aagaard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
1422
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Aagaard L, Askou A, Corydon T
Ugeskr Laeger
. 2024 Dec;
186(48).
PMID: 39651696
No abstract available.
2.
Haldrup S, Fabian-Jessing B, Jakobsen T, Lindholm A, Adsersen R, Aagaard L, et al.
Mol Ther Methods Clin Dev
. 2024 Apr;
32(2):101242.
PMID: 38605811
Neovascular age-related macular degeneration (nAMD) is a frequent cause of vision loss among the elderly in the Western world. Current disease management with repeated injections of anti-VEGF agents accumulates the...
3.
Corydon I, Fabian-Jessing B, Jakobsen T, Jorgensen A, Jensen E, Askou A, et al.
Mol Ther Nucleic Acids
. 2023 Aug;
33:469-482.
PMID: 37583575
The year 2023 marks the 25th anniversary of the discovery of RNAi. RNAi-based therapeutics enable sequence-specific gene knockdown by eliminating target RNA molecules through complementary base-pairing. A systematic review of...
4.
Cecchi C, Alsing S, Jesus G, Zacarias E, Kjaer L, Clement M, et al.
Tissue Cell
. 2023 Apr;
82:102095.
PMID: 37087908
Growth hormone (GH) deficiency is characterized by impaired growth and development, and is currently treated by repeated administration of recombinant human GH (hGH). Encapsulated cell therapy (ECT) may offer a...
5.
Dietz L, Furman N, Larsen T, Daugaard T, Thomsen E, Keller J, et al.
J Immunother
. 2022 Aug;
45(9):379-388.
PMID: 36036966
Antibody-based immunotherapy targeting the interaction between programmed cell death 1 (PD-1) and its ligand PD-L1 has shown impressive clinical outcomes in various cancer types, including nonsmall cell lung cancer (NSCLC)....
6.
Fabian-Jessing B, Jakobsen T, Jensen E, Alsing S, Hansen S, Aagaard L, et al.
Invest Ophthalmol Vis Sci
. 2022 Aug;
63(9):11.
PMID: 35943733
Purpose: Animal models of choroidal neovascularization (CNV) are extensively used to characterize the pathophysiology of chorioretinal diseases with CNV formation and to evaluate novel treatment strategies. This systematic review aims...
7.
Alsing S, Doktor T, Askou A, Jensen E, Ahmadov U, Kristensen L, et al.
Mol Ther Nucleic Acids
. 2022 Mar;
28:58-76.
PMID: 35356684
Retinal gene therapy using RNA interference (RNAi) to silence targeted genes requires both efficacy and safety. Short hairpin RNAs (shRNAs) are useful for RNAi, but high expression levels and activity...
8.
Wen J, Cao T, Wu J, Chen Y, Zhi S, Huang Y, et al.
Mol Ther
. 2021 May;
30(1):164-174.
PMID: 33992807
Transthyretin (TTR) amyloidosis is a hereditary life-threatening disease characterized by deposition of amyloid fibrils. The main causes of TTR amyloidosis are mutations in the TTR gene that lead to the...
9.
Fogh S, Dipace G, Bie A, Veiga-da-Cunha M, Hansen J, Kjeldsen M, et al.
J Inherit Metab Dis
. 2021 May;
44(5):1215-1225.
PMID: 33973257
Ethylmalonic acid (EMA) is a major and potentially cytotoxic metabolite associated with short-chain acyl-CoA dehydrogenase (SCAD) deficiency, a condition whose status as a disease is uncertain. Unexplained high EMA is...
10.
Wen J, Wu J, Cao T, Zhi S, Chen Y, Aagaard L, et al.
Transgenic Res
. 2021 Jan;
30(1):63-76.
PMID: 33394315
Taking advantage of their ability to integrate their genomes into the host genome, lentiviruses have been used to rapidly produce transgenic mice in biomedical research. In most cases, transgenes delivered...